NASDAQ:EYES

Second Sight Medical Products Competitors

$7.36
-0.84 (-10.24 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.09
Now: $7.36
$7.62
50-Day Range
$1.43
MA: $8.90
$15.48
52-Week Range
$0.69
Now: $7.36
$20.00
Volume2.31 million shs
Average Volume21.93 million shs
Market Capitalization$171.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49

Competitors

Second Sight Medical Products (NASDAQ:EYES) Vs. CUTR, ZYXI, EDAP, BSGM, FONR, and IRIX

Should you be buying EYES stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Second Sight Medical Products, including Cutera (CUTR), Zynex (ZYXI), Edap Tms (EDAP), BioSig Technologies (BSGM), FONAR (FONR), and IRIDEX (IRIX).

Second Sight Medical Products (NASDAQ:EYES) and Cutera (NASDAQ:CUTR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Institutional & Insider Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 87.8% of Cutera shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 2.3% of Cutera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Second Sight Medical Products and Cutera's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million50.63$-33,590,000.00($1.91)-3.85
Cutera$181.71 million2.95$-12,350,000.00($0.88)-34.28

Cutera has higher revenue and earnings than Second Sight Medical Products. Cutera is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, Cutera has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Second Sight Medical Products and Cutera, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
Cutera01302.75

Cutera has a consensus price target of $30.6667, suggesting a potential upside of 1.65%. Given Cutera's higher possible upside, analysts plainly believe Cutera is more favorable than Second Sight Medical Products.

Profitability

This table compares Second Sight Medical Products and Cutera's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
Cutera-18.83%-61.21%-25.31%

Summary

Cutera beats Second Sight Medical Products on 8 of the 13 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Institutional & Insider Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 29.6% of Zynex shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 50.5% of Zynex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Second Sight Medical Products and Zynex's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million50.63$-33,590,000.00($1.91)-3.85
Zynex$45.47 million11.77$9.49 million$0.2854.86

Zynex has higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Second Sight Medical Products and Zynex, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
Zynex02202.50

Zynex has a consensus price target of $21.6250, suggesting a potential upside of 40.79%. Given Zynex's higher possible upside, analysts plainly believe Zynex is more favorable than Second Sight Medical Products.

Profitability

This table compares Second Sight Medical Products and Zynex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
Zynex18.08%50.67%35.56%

Summary

Zynex beats Second Sight Medical Products on 10 of the 13 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Profitability

This table compares Second Sight Medical Products and Edap Tms' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
Edap Tms-4.03%-11.54%-5.78%

Risk and Volatility

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.

Earnings and Valuation

This table compares Second Sight Medical Products and Edap Tms' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million50.63$-33,590,000.00($1.91)-3.85
Edap Tms$50.23 million5.27$1.69 million$0.06151.33

Edap Tms has higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Second Sight Medical Products and Edap Tms, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
Edap Tms00303.00

Edap Tms has a consensus price target of $12.50, suggesting a potential upside of 37.67%. Given Edap Tms' higher possible upside, analysts plainly believe Edap Tms is more favorable than Second Sight Medical Products.

Summary

Edap Tms beats Second Sight Medical Products on 7 of the 13 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Second Sight Medical Products and BioSig Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
BioSig TechnologiesN/A-244.64%-213.88%

Volatility and Risk

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500.

Valuation and Earnings

This table compares Second Sight Medical Products and BioSig Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million50.63$-33,590,000.00($1.91)-3.85
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A

Second Sight Medical Products has higher revenue and earnings than BioSig Technologies.

Institutional and Insider Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 18.3% of BioSig Technologies shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 19.5% of BioSig Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Second Sight Medical Products and BioSig Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
BioSig Technologies0000N/A

Summary

Second Sight Medical Products beats BioSig Technologies on 4 of the 7 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Second Sight Medical Products and FONAR's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
FONAR8.28%5.57%3.99%

Volatility and Risk

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Valuation and Earnings

This table compares Second Sight Medical Products and FONAR's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million50.63$-33,590,000.00($1.91)-3.85
FONAR$85.69 million1.40$8.24 millionN/AN/A

FONAR has higher revenue and earnings than Second Sight Medical Products.

Institutional and Insider Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Second Sight Medical Products and FONAR, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
FONAR0000N/A

Summary

FONAR beats Second Sight Medical Products on 7 of the 10 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Second Sight Medical Products and IRIDEX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
IRIDEX-21.54%-38.60%-24.99%

Volatility and Risk

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Valuation and Earnings

This table compares Second Sight Medical Products and IRIDEX's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million50.63$-33,590,000.00($1.91)-3.85
IRIDEX$43.45 million2.75$-8,810,000.00($0.64)-12.05

IRIDEX has higher revenue and earnings than Second Sight Medical Products. IRIDEX is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 32.6% of IRIDEX shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 2.0% of IRIDEX shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Second Sight Medical Products and IRIDEX, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
IRIDEX00203.00

IRIDEX has a consensus price target of $6.50, suggesting a potential downside of 15.69%. Given IRIDEX's higher possible upside, analysts clearly believe IRIDEX is more favorable than Second Sight Medical Products.

Summary

IRIDEX beats Second Sight Medical Products on 8 of the 13 factors compared between the two stocks.


Second Sight Medical Products Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cutera logo
CUTR
Cutera
1.3$30.17-1.8%$536.51 million$181.71 million-16.67News Coverage
Zynex logo
ZYXI
Zynex
1.8$15.36-0.2%$535.37 million$45.47 million46.55
Edap Tms logo
EDAP
Edap Tms
1.3$9.08-0.3%$264.61 million$50.23 million-151.33Increase in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.88-4.4%$123.35 millionN/A0.00
FONR
FONAR
1.1$18.32-2.9%$120.07 million$85.69 million17.28News Coverage
IRIDEX logo
IRIX
IRIDEX
0.9$7.71-3.0%$119.67 million$43.45 million-14.02
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.15-2.6%$91.68 millionN/A-1.51Increase in Short Interest
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.18-1.8%$90.69 million$10,000.00-1.18Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.79-1.7%$86.77 million$2.39 million-2.27Decrease in Short Interest
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$16.90-1.3%$39.06 million$1.50 million-0.97Analyst Upgrade
Increase in Short Interest
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.37-0.4%$32.42 million$5.51 million-0.11Analyst Downgrade
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63-5.7%$27.20 million$6.57 million-0.01
STRR
Star Equity
0.1$2.80-5.4%$13.78 million$114.18 million-0.89
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.